Authorization

Avid Bioservices Reports Financial Results for Third Quarter Fiscal 2021 and Recent Developments

-- Third Quarter Revenue Increased 61% to $21.8 Million --
-- Signed $74 Million in New Orders to End the Quarter with a Backlog of $120 Million ---- First Phase of Myford Expansion on Target, Accelerated Start of Second Phase ---- Raised Gross Proceeds of $34.5 Million in Follow-On Equity Offering ---- Revenue Guidance for Fiscal 2021 Increased to $88 to $91 Million --
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Апрель 2021    »
ПнВтСрЧтПтСбВс
 1234
567891011
12131415161718
19202122232425
2627282930